TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR
Highlights • We evaluated the effects of therapy with PEG-IFN in patients with HDV-3 and correlated them with a possible cure rate higher than expected. • Therapeutic protocol used presents satisfactory response levels to orient the virologic response (VR)portion of the treated subjects. • HDV patie...
Gespeichert in:
| Veröffentlicht in: | International journal of infectious diseases 2016 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | International journal of infectious diseases |
| container_volume | |
| creator | Borzacov, Lourdes Maria Pinheiro Nicolete, Larissa Deadame de Figueiredo Silva, Luan Felipo Botelho da Santos, Alcione Oliveira dos Vieira, Deusilene Souza Salcedo, Juan Miguel Villalobos |
| description | Highlights • We evaluated the effects of therapy with PEG-IFN in patients with HDV-3 and correlated them with a possible cure rate higher than expected. • Therapeutic protocol used presents satisfactory response levels to orient the virologic response (VR)portion of the treated subjects. • HDV patients in the Amazon region can be treated with a combination of PEG-IFN alpha and Entecavir for 48 weeks, with good chances of Negative HDV RNA at week 24. • Our results suggest that HDV-3 in the native population may be an “easy to treat” variant compared to HDV-1. |
| doi_str_mv | 10.1016/j.ijid.2016.03.017 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier</sourceid><recordid>TN_cdi_elsevier_clinicalkeyesjournals_1_s2_0_S1201971216310049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1201971216310049</els_id><sourcerecordid>1_s2_0_S1201971216310049</sourcerecordid><originalsourceid>FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S12019712163100493</originalsourceid><addsrcrecordid>eNqljk0KwjAQRrNQ8PcCrnKBxkwrVTdCqdM2C9NSg-IqiEZILQoGBW9vBG_gauZ9fDM8QibAGXCIpw2zjT2z0O-MR4zDvEP64DFYziHskYFzDed8FseLPslVjYnaoFS0zGix3tEcZakOFdKICplhqkQp6V6oglaYB0IqrDOsfZbINfV3mCY7UY9I93JsnRn_5pCsMlRpERgPL2se-tTamz0d26t5G9fcn4-b72nQLtRcb79-Xz2II_Buy-jvBx9-L0vO</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR</title><source>Elsevier ScienceDirect Journals Complete</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Borzacov, Lourdes Maria Pinheiro ; Nicolete, Larissa Deadame de Figueiredo ; Silva, Luan Felipo Botelho da ; Santos, Alcione Oliveira dos ; Vieira, Deusilene Souza ; Salcedo, Juan Miguel Villalobos</creator><creatorcontrib>Borzacov, Lourdes Maria Pinheiro ; Nicolete, Larissa Deadame de Figueiredo ; Silva, Luan Felipo Botelho da ; Santos, Alcione Oliveira dos ; Vieira, Deusilene Souza ; Salcedo, Juan Miguel Villalobos</creatorcontrib><description>Highlights • We evaluated the effects of therapy with PEG-IFN in patients with HDV-3 and correlated them with a possible cure rate higher than expected. • Therapeutic protocol used presents satisfactory response levels to orient the virologic response (VR)portion of the treated subjects. • HDV patients in the Amazon region can be treated with a combination of PEG-IFN alpha and Entecavir for 48 weeks, with good chances of Negative HDV RNA at week 24. • Our results suggest that HDV-3 in the native population may be an “easy to treat” variant compared to HDV-1.</description><identifier>ISSN: 1201-9712</identifier><identifier>DOI: 10.1016/j.ijid.2016.03.017</identifier><language>eng</language><subject>Infectious Disease ; Pulmonary/Respiratory</subject><ispartof>International journal of infectious diseases, 2016</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,4024,27923,27924,27925</link.rule.ids></links><search><creatorcontrib>Borzacov, Lourdes Maria Pinheiro</creatorcontrib><creatorcontrib>Nicolete, Larissa Deadame de Figueiredo</creatorcontrib><creatorcontrib>Silva, Luan Felipo Botelho da</creatorcontrib><creatorcontrib>Santos, Alcione Oliveira dos</creatorcontrib><creatorcontrib>Vieira, Deusilene Souza</creatorcontrib><creatorcontrib>Salcedo, Juan Miguel Villalobos</creatorcontrib><title>TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR</title><title>International journal of infectious diseases</title><description>Highlights • We evaluated the effects of therapy with PEG-IFN in patients with HDV-3 and correlated them with a possible cure rate higher than expected. • Therapeutic protocol used presents satisfactory response levels to orient the virologic response (VR)portion of the treated subjects. • HDV patients in the Amazon region can be treated with a combination of PEG-IFN alpha and Entecavir for 48 weeks, with good chances of Negative HDV RNA at week 24. • Our results suggest that HDV-3 in the native population may be an “easy to treat” variant compared to HDV-1.</description><subject>Infectious Disease</subject><subject>Pulmonary/Respiratory</subject><issn>1201-9712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqljk0KwjAQRrNQ8PcCrnKBxkwrVTdCqdM2C9NSg-IqiEZILQoGBW9vBG_gauZ9fDM8QibAGXCIpw2zjT2z0O-MR4zDvEP64DFYziHskYFzDed8FseLPslVjYnaoFS0zGix3tEcZakOFdKICplhqkQp6V6oglaYB0IqrDOsfZbINfV3mCY7UY9I93JsnRn_5pCsMlRpERgPL2se-tTamz0d26t5G9fcn4-b72nQLtRcb79-Xz2II_Buy-jvBx9-L0vO</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Borzacov, Lourdes Maria Pinheiro</creator><creator>Nicolete, Larissa Deadame de Figueiredo</creator><creator>Silva, Luan Felipo Botelho da</creator><creator>Santos, Alcione Oliveira dos</creator><creator>Vieira, Deusilene Souza</creator><creator>Salcedo, Juan Miguel Villalobos</creator><scope/></search><sort><creationdate>2016</creationdate><title>TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR</title><author>Borzacov, Lourdes Maria Pinheiro ; Nicolete, Larissa Deadame de Figueiredo ; Silva, Luan Felipo Botelho da ; Santos, Alcione Oliveira dos ; Vieira, Deusilene Souza ; Salcedo, Juan Miguel Villalobos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S12019712163100493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Infectious Disease</topic><topic>Pulmonary/Respiratory</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borzacov, Lourdes Maria Pinheiro</creatorcontrib><creatorcontrib>Nicolete, Larissa Deadame de Figueiredo</creatorcontrib><creatorcontrib>Silva, Luan Felipo Botelho da</creatorcontrib><creatorcontrib>Santos, Alcione Oliveira dos</creatorcontrib><creatorcontrib>Vieira, Deusilene Souza</creatorcontrib><creatorcontrib>Salcedo, Juan Miguel Villalobos</creatorcontrib><jtitle>International journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borzacov, Lourdes Maria Pinheiro</au><au>Nicolete, Larissa Deadame de Figueiredo</au><au>Silva, Luan Felipo Botelho da</au><au>Santos, Alcione Oliveira dos</au><au>Vieira, Deusilene Souza</au><au>Salcedo, Juan Miguel Villalobos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR</atitle><jtitle>International journal of infectious diseases</jtitle><date>2016</date><risdate>2016</risdate><issn>1201-9712</issn><abstract>Highlights • We evaluated the effects of therapy with PEG-IFN in patients with HDV-3 and correlated them with a possible cure rate higher than expected. • Therapeutic protocol used presents satisfactory response levels to orient the virologic response (VR)portion of the treated subjects. • HDV patients in the Amazon region can be treated with a combination of PEG-IFN alpha and Entecavir for 48 weeks, with good chances of Negative HDV RNA at week 24. • Our results suggest that HDV-3 in the native population may be an “easy to treat” variant compared to HDV-1.</abstract><doi>10.1016/j.ijid.2016.03.017</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1201-9712 |
| ispartof | International journal of infectious diseases, 2016 |
| issn | 1201-9712 |
| language | eng |
| recordid | cdi_elsevier_clinicalkeyesjournals_1_s2_0_S1201971216310049 |
| source | Elsevier ScienceDirect Journals Complete; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Infectious Disease Pulmonary/Respiratory |
| title | TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TREATMENT%20OF%20HDV%20GENOTYPE%203%20INFECTION%20WITH%20PEG-INTERFERON%20AND%20ENTECAVIR&rft.jtitle=International%20journal%20of%20infectious%20diseases&rft.au=Borzacov,%20Lourdes%20Maria%20Pinheiro&rft.date=2016&rft.issn=1201-9712&rft_id=info:doi/10.1016/j.ijid.2016.03.017&rft_dat=%3Celsevier%3E1_s2_0_S1201971216310049%3C/elsevier%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=1_s2_0_S1201971216310049&rfr_iscdi=true |